New drug OVV-01 injected into tumors shows promise in early trial
NCT ID NCT07648472
First seen Jun 19, 2026 · Last updated Jun 19, 2026
Summary
This early-phase study is testing a new drug called OVV-01 in 18 people with advanced solid tumors that have not responded to standard treatments. The drug is given either through a vein or directly into a tumor. The main goal is to check safety and find the right dose, while also looking for signs that the drug can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
OVV-01 (a drug injected into a vein or directly into a tumor)
What this could lead to
If this works, it could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This is a very early, small Phase 1 trial with only 18 people, focused mainly on safety. It may not show clear benefit, and side effects are unknown. Success is far from guaranteed.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.